The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort

Rheumatology (Oxford). 2017 Jun 1;56(6):1019-1024. doi: 10.1093/rheumatology/kew387.


Objective: The aim was to correlate protein concentrations of S100A9 in pretreatment serum samples with response to the tumour-necrosis factor (TNF) inhibitor drugs etanercept in a large UK replication cohort.

Methods: Pretreatment serum samples from patients with RA (n = 236) about to commence treatment with etanercept had S100A9 serum concentration measured using an ELISA. Following the experimental procedure, S100A9 concentrations were analysed with respect to EULAR response.

Results: No evidence of association between S100A9 concentration and EULAR response to the TNF-inhibitor biologic drug etanercept was observed following multinomial logistic regression analysis (non-responder vs moderate responder, P = 0.957; and non-responder vs good responder, P = 0.316). Furthermore, no significant associations were observed when correlating pretreatment S100A9 concentrations with clinical parameters of disease activity (P > 0.05).

Conclusion: In the largest replication cohort conducted to date, no evidence for association was observed to support the use of S100A9 as a clinical biomarker predictive of response to the TNF-inhibitor biologic drug etanercept.

Keywords: biomarker; etanercept; precision medicine; protein; rheumatoid arthritis; treatment response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / drug therapy*
  • Biomarkers / metabolism
  • Calgranulin B / metabolism*
  • Enzyme-Linked Immunosorbent Assay
  • Etanercept / therapeutic use*
  • Female
  • Humans
  • Male
  • Treatment Outcome


  • Antirheumatic Agents
  • Biomarkers
  • Calgranulin B
  • Etanercept